• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:张长青,张葵玲,王育斌,林志金,黄奕森.米曲菌酶联合伊托必利辅助治疗慢性胃炎伴反流性食管炎的疗效观察[J].中国现代应用药学,2019,36(12):1556-1560.
ZHANG Changqing,ZHANG Kuiling,WANG Yubin,LIN Zhijin,HUANG Yisen.Effect of Aspergillus Oryzae Combined with Itopril in the Adjuvant Treatment of Chronic Gastritis with Reflux Esophagitis[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(12):1556-1560.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2044次   下载 1241 本文二维码信息
码上扫一扫!
分享到: 微信 更多
米曲菌酶联合伊托必利辅助治疗慢性胃炎伴反流性食管炎的疗效观察
张长青, 张葵玲, 王育斌, 林志金, 黄奕森
福建医科大学附属泉州第一医院消化内科, 福建 泉州 362000
摘要:
目的 探讨米曲菌酶联合伊托必利辅助治疗慢性胃炎伴反流性食管炎的疗效。方法 选取2017年6月-2018年6月福建医科大学附属泉州第一医院收治的慢性胃炎伴反流性食管炎患者60例,采用随机数字表法分为2组,各30例。对照组给予口服盐酸伊托必利片,治疗组在对照组基础上口服米曲菌胰酶片,2组患者均连续治疗8周。观察2组患者临床疗效、反流性食管炎症状积分、内镜检查结果分级、SF-36评分、SDS评分、SAS评分和不良反应发生情况。结果 治疗后,治疗组总有效率显著优于对照组(P<0.05);2组胸骨后烧痛、烧心和反酸评分显著降低,治疗组降低更显著(P<0.05);2组患者胃镜检查显著改善,治疗组0级和1级例数显著多于对照组,3级和4级例数显著少于对照组(P<0.05);2组SF-36评分显著升高,治疗组SF-36评分升高更明显(P<0.001);2组患者SDS评分和SAS评分显著降低,治疗组下降程度更明显(P<0.001)。结论 采用米曲菌酶联合伊托必利辅助治疗慢性胃炎伴反流性食管炎,具有较好的临床疗效,能够有效地缓解临床症状,值得在临床上推广应用。
关键词:  米曲菌酶  伊托必利  慢性胃炎伴反流性食管炎  疗效观察
DOI:10.13748/j.cnki.issn1007-7693.2019.12.021
分类号:R969.4
基金项目:
Effect of Aspergillus Oryzae Combined with Itopril in the Adjuvant Treatment of Chronic Gastritis with Reflux Esophagitis
ZHANG Changqing, ZHANG Kuiling, WANG Yubin, LIN Zhijin, HUANG Yisen
Department of Gastroenterology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, China
Abstract:
OBJECTIVE To investigate the curative effect of aspergillus oryzae combined with itopril in the adjuvant treatment of chronic gastritis with reflux esophagitis. METHODS Sixty cases of chronic gastritis with reflux esophagitis admitted to Quanzhou First Hospital Affiliated to Fujian Medical University from June 2017 to June 2018 were selected and divided into 2 groups of 30 cases each by random number table method. The control group was given oral itopride hydrochloride tablets, the treatment group was based on the control group of Oral Aspergillus pancreatic enzyme, 2 groups of patients were continuous treatment of 8 weeks. The clinical efficacy, reflux esophageal inflammatory status score, endoscopic grading, SF-36 score, SDS score, SAS score and adverse reactions were observed in the 2 groups. RESULTS After treatment, the total effective rate of the treatment group was significantly better than that of the control group(P<0.05). The scores of retrosternal burning pain, heartburn and acid regurgitation were significantly decreased in the 2 groups, the decrease was more significant in the treatment group(P<0.05). Gastroscopy was significantly improved in both groups, the number of grade 0 and grade 1 patients in the treatment group was significantly higher than that in the control group(P<0.05), and the number of grade 3 and grade 4 patients was significantly lower than that in the control group. SF-36 scores were significantly increased in both groups, the SF-36 score of the treatment group was significantly increased(P<0.05). SDS and SAS scores of the 2 groups were significantly lower than those before treatment(P<0.05). The degree of decline was more significant in the treatment group(P<0.05). CONCLUSION The use of aspergillus oryzae combined with itopride adjuvant treatment of chronic gastritis with reflux esophagitis has a good clinical effect, can effectively alleviate the clinical symptoms, worthy of clinical application.
Key words:  aspergillus oryzae  itobili  chronic gastritis with reflux esophagitis  clinical observation
扫一扫关注本刊微信